Background-Left ventricular hypertrophy (LVH) occurs as an adaptive response to a physiological (such as exercise) or pathological (valvular disease, hypertension, or obesity) increase in cardiac work. The molecular mechanisms regulating the LVH response are poorly understood. However, inherited defects in fatty acid oxidation are known to cause severe early-onset cardiac hypertrophy. Peroxisome proliferator-activated receptor ␣ (PPAR␣) regulates genes responsible for myocardial fatty acid oxidation and is downregulated during cardiac hypertrophy, concomitant with the switch from fatty acid to glucose utilization. Methods and Results-The role of PPAR␣ in left ventricular growth was investigated in 144 young male British Army recruits undergoing a 10-week physical training program and in 1148 men and women participating in the echocardiographic substudy of the Third Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) Augsburg study. A G/C polymorphism in intron 7 of the PPAR␣ gene significantly influenced left ventricular (LV) growth in response to exercise (Pϭ0.009). LV mass increased by 6.7Ϯ1.5 g in G allele homozygotes but was significantly greater in heterozygotes for the C allele (11.8Ϯ1.9 g) and in CC homozygotes (19.4Ϯ4.2 g). Likewise, C allele homozygotes had significantly higher LV mass, which was greater still in hypertensive subjects, and a higher prevalence of LVH in the Third MONICA Augsburg study.
L eft ventricular hypertrophy (LVH) is generally understood to be an adaptive response to increased workload. In fact, both physiological and pathological stimuli (valvular disease, hypertension, obesity, and exercise 1 ) may stimulate cardiac growth. In addition, mutations in genes encoding sarcomeric proteins affecting contractility may cause LVH. 2 LVH is an independent risk factor for cardiovascular morbidity and mortality 3, 4 through largely unknown mechanisms. However, studies in related 5 and unrelated 6 individuals clearly demonstrate that a high proportion of interindividual variability in left ventricular mass and risk of LVH is attributable to genetic factors. 7 An important molecular adaptation in the hypertrophied heart is the increase in glucose utilization and decrease in fatty acid oxidation (FAO) attributable to downregulation of FAO enzyme mRNA levels. 8 Defects in mitochondrial FAO enzymes cause childhood hypertrophic cardiomyopathy, 9 and perturbation of FAO in animal models causes cardiac hypertrophy, 10, 11 indicating that substrate utilization is important in the pathogenesis of hypertrophy. Peroxisome proliferator-activated receptor ␣ (PPAR␣) is a ligand-activated transcription factor 12 that regulates the expression of genes involved in fatty acid (FA) uptake and oxidation, lipid metabolism, and inflammation. 13 Ligands for PPAR␣ include long-chain fatty acids 14 and the fibrate class of lipid-lowering drugs. 15 PPAR␣ is expressed at high levels in tissues that catabolize FA, such as the liver, skeletal muscle, and heart. 16 PPAR␣ regulates the expression of cardiac mitochondrial FAO enzymes 17 and is downregulated during cardiac hypertrophy in vitro and in vivo, leading to reduced FAO and impaired cellular lipid homeostasis. 18 PPAR␣-knockout mice have markedly reduced FAO and exhibit cardiac lipid accumulation and fibrosis 19 and die on inhibition of mitochondrial fatty acid uptake. 20 The influence of PPAR␣ on cardiac growth was examined using the previously described functional leucine 162 valine (L162V) variant 21 and a novel G/C polymorphism in intron 7 of the human PPAR␣ gene. In particular, the role of PPAR␣ in the physiological left ventricular hypertrophic response to exercise was examined in 144 young male British Army recruits undergoing an intense 10-week physical training program. 22 The role of PPAR␣ in the pathophysiological response to hypertension was investigated in a populationbased sample of 1148 German men and women participating in the Third Monitoring Trends and Determinants in Cardiovascular Disease (MONICA) Augsburg survey. 23
Methods

Study Populations
The army exercise study comprises 144 healthy normotensive white male British Army recruits, selected for homozygosity of the angiotensin-converting enzyme (ACE) insertion/deletion (I/D) genotype, randomized to receive placebo or 25 mg/d losartan, an AT 1 receptor antagonist, throughout a 10-week training program. Recruits underwent an identical standard supervised training regime consisting of mixed upper and lower body strength and endurance training. At the start and end of training, height, weight and blood pressure were determined and cardiac MRI was performed. Briefly, 10-mm ECG-gated short-axis cardiac images (single breath holding, 0.5T) were obtained, and left ventricular (LV) mass was determined by multiplying myocardial tissue volume by myocardial tissue-specific density. Chamber volumes were calculated by summing end-diastolic and end-systolic endocardial areas in each slice. 22 The effects of environmental variation are minimized by the racial, age, and sex homogeneity of the cohort, the absence of cardiorespiratory disease, identical living quarters and clothing, and access to a highcarbohydrate diet.
The echocardiographic substudy of the third MONICA Augsburg survey has been previously described. 23 Subjects originate from a sex-and age-stratified random sample of all German residents of the Augsburg study area aged 25 to 74 years. Hypertension was defined as systolic blood pressure Ն160 mm Hg or diastolic blood pressure Ն95 mm Hg or intake of antihypertensive medication during the 7 days preceding the examination. A 2-dimensionally guided M-mode echocardiogram was performed on each subject. Structures for M-mode-guided calculation of LVM were measured according to the guidelines of the American Society of Echocardiography, and LVM was calculated and indexed to body surface area as LVM index in g/m 2 of body surface area. LVH was defined when LVM index was Ͼ134 g/m 2 body surface area in men or Ͼ110 g/m 2 body surface area in women.
Genotype Determination
Genotyping was carried out by polymerase chain reaction (PCR) and restriction enzyme digestion. PPAR␣ L162V and ACE I/D genotyping was performed as previously described. 21 PCR primers were forward ACAATCACTCCTTAAATATGGTGG and reverse AAGTAGGGACAGACAGGACCAGTA, generating a fragment of 266 bp. PCR products were digested with 3 U TaqI (Helena Biotech) for 4 hours at 65°C and analyzed using the microtiter array diagonal gel electrophoresis system. 24
Statistical Analysis
Association between PPAR␣ genotype and variables was analyzed using SPSS 6.1 statistical package and SAS 6.12 statistical software. Allele frequencies were determined by the gene-counting method. The effect of PPAR␣ genotype at baseline and after training characteristics in BigHeart 2 was examined by ANOVA and multiple linear regression. The effect of intron 7 genotype in the Third MONICA Augsburg study was investigated by multiple linear regression with age, body mass index (BMI), sex (where necessary), systolic blood pressure, and antihypertensive medication in the models.
Results
The intron 7 polymorphism, originally reported as a TaqI RFLP, 25 was found by direct sequencing to be a G to C transversion at nt 2528 of intron 7 of the PPAR␣ gene.
Effects in Response to Exercise
Intron 7 and L162V genotypes were determined in 144 young healthy male white British Army recruits, randomized to receive either low-dose Losartan or placebo. Losartan treatment did not affect LV growth. 22 Intron 7 C allele frequency was 0.181 (95%CI, 0.136 to 0.225), V162 allele frequency was 0.074 (95% CI, 0.043 to 0.105), and genotype distributions were in Hardy-Weinberg equilibrium ( Table 1) . At baseline, age, weight, BMI, systolic and diastolic blood pressure, and measures of heart size were not significantly different between genotypes (not shown). With 10 weeks of an intense training program, LV mass determined by cardiac magnetic resonance increased significantly by 8.6Ϯ1.2 g (PϽ0.0001). This increase in LV mass was significantly influenced by intron 7 genotype (Pϭ0.009), being modest among those of GG genotype (6.7Ϯ1.5 g), significantly greater in heterozygotes for the C allele (11.8Ϯ1.9 g), and 3-fold greater in CC homozygotes (19.4Ϯ4.2 g) ( Figure 1A ). These effects remained significant when LV mass was adjusted for body surface area (Pϭ0.02) or lean mass Figure 1B) . Given that participants were selected for homozygosity for the ACE gene I/D polymorphism, 22 we also examined for interaction between the ACE I/D and PPAR␣ intron 7 genotypes. This analysis revealed that the ACE I/D and PPAR␣ intron 7 genotypes had an independent effect on change in LV mass (ACE, Pϭ0.003; PPAR␣, Pϭ0.026). Subjects of II/GG genotype exhibited the lowest cardiac growth, whereas the individuals of DD/CC genotype exhib-ited the greatest exercise-related growth ( Figure 1C ). In a multiple regression model including all 3 genotypes determined, the effect on change in LV mass is calculated as ϩ7.47Ϯ2.37 g for ACE DD, ϩ5.06Ϯ2.80 g for carriers of the intron 7 C allele, ϩ15.61Ϯ6.45g for intron 7 C allele homozygotes, and Ϫ6.2Ϯ3.74g for carriers of the V162 allele compared with ACE II, PPAR␣ L162V LL, and intron 7 GG genotypes. Total variance in LV growth attributable to ACE I/D genotype was 8% (Pϭ0.002), PPAR␣ intron 7 genotype was 6% (Pϭ0.026), and PPAR␣ L162V genotype was 2.2% (Pϭ0.1).
Effects in Response to Hypertension
To examine whether PPAR␣ influences LV growth in response to pathophysiological stimuli, L162V and intron 7 genotype was determined in 578 men and 564 women participating in the echocardiographic substudy of the third MONICA Augsburg survey. 23 V162 allele frequency was 0.065 (95% CI, 0.055 to 0.075) and intron 7 C allele frequency was 0.179 (95% CI, 0.163 to 0.195), and the V162 and intron 7 C alleles showed significant allelic association. Both polymorphisms were in Hardy-Weinberg equilibrium. There was no difference in age, BMI, or plasma lipid measures between L162V or intron 7 genotypes (data not shown). Systolic blood pressure was on average 6.8 mm Hg lower in male intron 7 C allele homozygotes than G allele homozygotes or C allele carriers (Pϭ0.13) ( Table 2 ). In multivariate regression analysis including age, antihypertensive medication, BMI, and systolic blood pressure, intron 7 genotype was significantly associated with left ventricular mass indexed to body surface area (LVMI) in men, with women showing a similar but nonsignificant trend. Male G allele homozygotes had an LVMI of 91.8Ϯ1.0, C allele carriers had an LVMI of 92.2Ϯ1.3 g/m 2 , whereas C allele homozygotes had 15% greater mean LVMI of 105.7Ϯ4.8 g/m 2 (Pϭ0.005). Female G allele homozygotes had an LVMI of 79.0Ϯ0.7 g/m 2 , C allele carriers had an LVMI of 78.7Ϯ1.2 g/m 2 , whereas C allele homozygotes had 7% higher LVMI of 84.6Ϯ3.8 g/m 2 (Pϭ0.14). Similar effects were observed on septum and posterior wall measurements in men, and in women posterior wall diameter was significantly greater in C allele homozygotes than in homozygotes or carriers of the C allele, although septal wall thickness was similar between genotypes in women ( Table 2 ). In the entire sample, with men and women combined, the hypertrophic effect of the CC genotype was highly significant for LVMI (CC 95.2Ϯ3.2 g/m 2 versus GGϩGC 84.8Ϯ0.5 g/m 2 , Pϭ0.001), posterior wall (CC 9.43Ϯ0.21 mm versus GGϩGC 8.66Ϯ0.03 mm, Pϭ0.0002), and septum (CC 11.26Ϯ0.29 mm versus GGϩGC 10.50Ϯ0.04 mm, Pϭ0.009).
Interestingly, the effect of PPAR␣ intron 7 genotype on LVMI was exacerbated in hypertensive individuals (nϭ319) (Figure 2 ). In normotensive individuals, C allele homozygotes had an LVMI of 87.3Ϯ3.2 g/m 2 (Pϭ0.04 versus GG homozygotes) compared with 80.5Ϯ0.6 g/m 2 in G allele homozygotes and 81.2Ϯ0.9 g/m 2 in C allele carriers (overall effect of genotype, Pϭ0.07) (Figure 2A ). Hypertensive C allele homozygotes had a significantly greater LVMI of 114.6Ϯ7.0 g/m 2 compared with 99.0Ϯ1.5 g/m 2 for G allele homozygotes (Pϭ0.03 CC versus GG) and 97.7Ϯ2.2 g/m 2 in C allele carriers (Pϭ0.02) ( Figure 2B ). Male C allele homozygotes were 4 times more likely to have clinically defined LVH than G allele homozygotes or C allele carriers (0.20 versus 0.05, Pϭ0.03), an effect not observed in females (0.13 versus 0.10, Pϭ0.89) (Figure 3 ). L162V genotype had no effect on LV measures (data not shown). No effect was observed on left ventricle end-diastolic dimensions, left atrial diameter, and aortic root diameter for either PPAR␣ genotype (data not shown).
Discussion
PPAR␣ plays a key role in the regulation of cardiac FA uptake and oxidation and may be the mediator, at least in part, of the metabolic switch from FA to glucose during hypertrophy. It is conceivable that PPAR␣ could influence cardiac growth through the modulation of cardiac FAO. The data presented support this notion, because they demonstrate that common variation in the PPAR␣ gene influences human LV growth in response to exercise and hypertension, 2 distinct stimuli that influence LVH. There is a growing body of evidence that appropriate substrate use is critical for cardiac function. Defects in FAO enzymes cause childhood cardiomyopathies, 9 and pharmacological inhibition of cardiac FA import induces cardiac hypertrophy 26 and causes rapid death in PPAR␣-knockout mice. 20 Transgenic mice that overexpress long-chain acyl-CoA synthetase and take up excess long chain fatty acids initially exhibit cardiac hypertrophy, followed by LV dysfunction and death. 11 These data clearly show that appropriate regulation of cardiac substrate use is essential for normal cardiac function.
Exercise-induced LV growth in healthy young men was strongly influenced by the intron 7 polymorphism of the PPAR␣ gene, an effect modulated by the L162V polymorphism. Individuals homozygous for the C allele had a 3-fold greater and heterozygotes had a 2-fold greater increase in LV mass than G allele homozygotes. The additive effect of the PPAR␣ intron 7 and ACE I/D polymorphisms indicates that these hypertrophic pathways act independently. Thus, PPAR␣ is a regulator of LV growth in response to an intense short-term physiological stimulus.
The PPAR␣ intron 7 polymorphism was also associated with left ventricular mass and the presence of clinically defined LVH in a population-based sample of the third MONICA Augsburg survey. The effect on left ventricular mass was much stronger in men, although women showed a similar nonsignificant trend, and was significant in the whole population when men and women were combined. The hypertrophic effect of the intron 7 C allele was Ϸ2-fold greater in hypertensive than normotensive subjects, indicating that PPAR␣ influences the degree of LV growth in response to hypertension but also influences growth in the absence of an obvious stimulus. The hypertrophic effect of the intron 7 C allele is not mediated through raised systolic blood pressure, because intron 7 C allele homozygotes have lower systolic blood pressure than G allele homozygotes or C allele carriers. In contrast to exercise-induced hypertrophy, in which an We hypothesize that these differences are attributable to the contrasting nature of a strong short-term exercise stimulus and the low-level long-term stimulus of hypertension. These data clearly demonstrate that PPAR␣ plays an important role in the regulation of LV growth in response to both exercise and blood pressure stimuli, thus identifying a novel pathway for the regulation of cardiac growth. The genetic contribution to total variance in LV mass is estimated at Ͼ60% in early pubertal children, 5 whereas heritability of LV mass was estimated at 0.24 to 0.32 in adults in the Framingham Study. 27 In the army study, PPAR␣ intron 7 and L162V genotypes explained 6% and 2.2% of total variance in change in LV mass in the study, whereas the ACE I/D genotype was responsible for an additional 8% of variance.
The sexually dimorphic effect on cardiac growth of PPAR␣ polymorphisms parallels effects observed in PPAR␣knockout mice. Male PPAR␣-knockout mice treated with etomoxir, an inhibitor of mitochondrial LCFA import, show massive hepatic and cardiac lipid accumulation and hypoglycemia, and all die after 4 days of treatment, whereas mortality is only 25% in females. The female mice that died also had severe hypoglycemia, and male mice exhibiting lethargy recovered on dextrose injection, indicating that severe hypoglycemia may be directly responsible for death. Male mice pretreated with estradiol were protected from the ill effects of etomoxir. 20 Aging male PPAR␣-knockout mice also exhibit hepatic steatohepatitis, whereas females show late-onset obesity and hypertriglyceridemia. 28 The mechanism by which the intron 7 polymorphism affects PPAR␣ function remains unclear. The intron 7 C allele is in allelic association with the V162 allele, which encodes a more transcriptionally active PPAR␣ 21 and attenuates the effect of the intron 7 C allele on exercise-induced LVH. We speculate that the intron 7 polymorphism is in allelic association with an unidentified variant in a regulatory region of the PPAR␣ gene that affects PPAR␣ levels, which in turn affect transcriptional activation of PPAR␣ target genes. Efforts to examine the effect of intron 7 genotype on PPAR␣ mRNA levels and to identify functional promoter variants are presently underway.
In summary, these data constitute strong evidence that PPAR␣ regulates left ventricular growth in response to exercise and hypertension stimuli and illustrate the important role of cardiac fatty acid metabolism in cardiac growth. These data may have therapeutic implications for patients with LVH. Stimulation of FAO by PPAR␣ activation with fibrates may prove a useful therapeutic strategy for treatment of a subset of patients with LVH.
